Launch week offerEnds in00h00m00s
annual Promonthly Pro
Elham Hedayati
Adjunct Senior Lecturer
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Elham Hedayati is an Adjunct Senior Lecturer at Karolinska Institutet in Sweden. Her research focuses on therapeutic drug monitoring, breast cancer survival rates, and the cardiovascular toxicity associated with cancer therapies. She has contributed to various studies that examine the quality of life and the socioeconomic impacts on patients with metastatic breast cancer. Her recent work emphasizes the importance of patient-centered approaches and clinical outcomes in oncology.
Positions (1)
Karolinska Institutet
Karolinska Institutet
5 months ago
PhD student opportunity in translational breast cancer research at Karolinska Institutet , within Linda Lindström’s research group . The project focuses on understanding why some patients with breast cancer develop metastatic disease and die from the disease, with particular attention to molecular oncology , tumour heterogeneity , endocrine therapy , and long-term risk. The group studies breast cancer cohorts with long follow-up and uses complementary approaches that combine clinical data, statistical analysis, molecular analyses, and newer methods such as spatial proteomics and image analysis . This is a fully funded PhD studentship with a contractual salary. The position is based in an interdisciplinary and international environment at Karolinska Institutet, with collaborations across the US, the Netherlands, Norway, and Spain. The doctoral student will work on analytical and practical tasks, scientific writing, seminars, and presentations, and may also contribute to coordination of patient information and molecular work. Applicants should have a background in computational biology , biostatistics , bioinformatics , or a related field. Strong interest in cancer research, data analysis, and interdisciplinary work is important. Required eligibility includes a master’s degree or equivalent advanced study, plus English proficiency equivalent to English B/English 6. Merits include experience with breast cancer research, cancer biology, R/Python, molecular biology, and high-throughput methods such as gene expression profiling or RNA/DNA sequencing. The application deadline is 25 June 2026 . Interested candidates should review the vacancy details and submit their application through the provided portal link.
5 months ago
Articles (15)
Year:
2026
Year:
2026
Year:
2025
Data are scarce on the role of pathogenic germline variants in BRCA1 and BRCA2 (gBRCAm) in subtype-specific survival in young women who develop breast cancer under the age of 40. This retrospective, real-world cohort study assessed the distant disease-free survival (DDFS) and overall survival (OS) of young women diagnosed with breast cancer between 2008 and 2019 while taking into consideration the interaction of clinical subtypes and the gBRCA status. Among 473 women, HR+/Her2− was the most common subtype (49.0%), followed by TNBC (31.3%), HR+/Her2+ (13.7%), and Her2+/HR− (5.9%). The gBRCA status was known for 319 cases (gBRCAwt (wild-type – without pathogenic variants in BRCA1 or BRCA2): 204, gBRCA1m: 83, gBRCA2m: 31, 1 patient with both). The distribution of clinical subtypes varied depending on the gBRCA status (p < 0.001). In survival analysis with a median follow-up of 43 months, the unadjusted DDFS and OS were worse for gBRCAwt TNBC compared to both HR+ subtypes, but not for gBRCAm TNBC patients. T-stage, nodal involvement, and the gBRCA status were identified as significant for survival in TNBC. In TNBC, gBRCAm was associated with better DDFS and OS than gBRCAwt (5-year DDFS 81.4% vs. 54.3%, p = 0.012 and 5-year OS 96.7% vs. 62.7%, p < 0.001). In contrast, in HR+/Her2− patients, gBRCAm patients showed a tendency for worse survival, though not statistically significant. Subtype-specific survival in young women with breast cancer needs to be evaluated in interaction with the gBRCA status. For TNBC, gBRCAm is of favorable prognostic value for overall survival, while patients with gBRCAwt TNBC need to be considered to have the highest risk for adverse survival outcomes.
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Collaborators (19)
Oscar Wiklander
Karolinska Institutet
Luzia Travado
Head
-
Angela Denise Ives
University of Western Australia
Lisa Rydén
Professor Surgery
Umeå Universitet Medicinska fakulteten
Yuki Seidler
Universität Wien
Anna Maria Hage
Charité - Universitätsmedizin Berlin
Narsis Kiani
Karolinska Institutet
Maria Margarete Karsten
Professor
Charité - Universitätsmedizin Berlin
Dan Granberg
Karolinska University Hospital
Therese Djärv
Karolinska Institutet
Carl Christofer Juhlin
Research group leader
Karolinska Institutet
linetta koppert
Associate professor
Erasmus MC
Dorothee Speiser
Charité - Universitätsmedizin Berlin
Regina Grossmann
Head Clinical Trials Center
University Hospital of Zurich
Aina Johnsson
Karolinska Institutet
Renske Altena-Kornalijnslijper
Karolinska University Hospital
Ivan Shabo
Karolinska Institutet
Irma Fredriksson
Karolinska University Hospital
Frida E Lundberg
Karolinska Institutet
Make your next move.
Prepare your application
Review drafts before you send them.